UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 184

Sortiert nach

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

PloS one, 2016-06, Vol.11 (6), p.e0158156

2016

Volltextzugriff (PDF)

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Nature communications, 2017-12, Vol.8 (1), p.2125-14, Article 2125

2017

Volltextzugriff (PDF)

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Annals of hematology, 2021-07, Vol.100 (7), p.1863-1870

2021

Volltextzugriff (PDF)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Frontiers in oncology, 2021-05, Vol.11 (16), p.664688-664688

2021

Volltextzugriff (PDF)

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Blood reviews, 2021-01, Vol.45, p.100695-100695, Article 100695

2021

Volltextzugriff (PDF)

Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose

Transfusion and apheresis science, 2021-02, Vol.60 (1), p.103081-103081, Article 103081

Reshef, Ran

2021

Volltextzugriff (PDF)

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Biology of blood and marrow transplantation, 2016-01, Vol.22 (1), p.4-10

2016

Volltextzugriff (PDF)

682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A774-A774

2023

Volltextzugriff (PDF)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN‐LABEL GLOBAL PHASE3 STUDY OF TAB‐CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

HemaSphere, 2023-08, Vol.7 (S3), p.e0490265-n/a

2023

Volltextzugriff (PDF)

P871: IDECABTAGENE VICLEUCEL (IDE‐CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA‐2 COHORT 2C

HemaSphere, 2023-08, Vol.7 (S3), p.e90596a3-n/a

2023

Volltextzugriff (PDF)

P1107: ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e6350662-n/a

2023

Volltextzugriff (PDF)

168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A101-A101

2020

Volltextzugriff (PDF)

Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen

Biology of blood and marrow transplantation, 2019-11, Vol.25 (11), p.2222-2227

2019

Volltextzugriff (PDF)

Arginine uptake is attenuated, through post-translational regulation of cationic amino acid transporter-1, in hyperlipidemic rats

Atherosclerosis, 2007-10, Vol.194 (2), p.357-363

2007

Volltextzugriff (PDF)

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.8026-8027

2022

Volltextzugriff (PDF)

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Blood, 2021-11, Vol.138 (Supplement 1), p.301-301

2021

Volltextzugriff (PDF)

NCMP-02. NEUROTOXICITY RELATED TO CAR T-CELL THERAPY IN PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi147-vi147

2021

Volltextzugriff (PDF)

Curative Allogeneic Stem Cell Transplantation Is Safe and Feasible in Adult Patients with Sickle Cell Disease Despite Lack of Matched Sibling Donor and Presence of Sickle Cell-Related Co-Morbidities

Blood, 2018-11, Vol.132 (Supplement 1), p.5713-5713

2018

Volltextzugriff (PDF)

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Blood, 2022-11, Vol.140 (Supplement 1), p.875-877

2022

Volltextzugriff (PDF)

Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Blood, 2022-11, Vol.140 (Supplement 1), p.7468-7469

2022

Volltextzugriff (PDF)

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.10318-10320

2022

Volltextzugriff (PDF)

Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients

Blood, 2019-11, Vol.134 (Supplement_1), p.4491-4491

2019

Volltextzugriff (PDF)

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

Blood, 2019-11, Vol.134 (Supplement_1), p.2043-2043

2019

Volltextzugriff (PDF)

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.6-7

2020

Volltextzugriff (PDF)

1 – 25 von 184

Suche als RSS-Feed

Aktive Filter

KollektionEbook Central Perpetual and DDA

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(145)
Mit Volltextzugriff
(183)

Publikationsform

Artikel
(183)
Berichte
(1)

Sprache

Englisch
(184)
Japanisch
(8)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN‐LABEL GLOBAL PHASE3 STUDY OF TAB‐CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

P871: IDECABTAGENE VICLEUCEL (IDE‐CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA‐2 COHORT 2C

P1107: ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target

Standardized Semi-structured Psychosocial Evaluation before Hematopoietic Stem Cell Transplantation Predicts Patient Adherence to Post-Transplant Regimen

Arginine uptake is attenuated, through post-translational regulation of cationic amino acid transporter-1, in hyperlipidemic rats

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

NCMP-02. NEUROTOXICITY RELATED TO CAR T-CELL THERAPY IN PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Curative Allogeneic Stem Cell Transplantation Is Safe and Feasible in Adult Patients with Sickle Cell Disease Despite Lack of Matched Sibling Donor and Presence of Sickle Cell-Related Co-Morbidities

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Autologous Transplant Recipients Have a Healthier Gut Microbiota at Baseline and Faster Recovery from Microbiome Injury Compared to Allogeneic Transplant Recipients

Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: Updated Results from a Single Center Experience

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Aktive Filter

Suchergebnisse filtern